Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy

by | Jan 1, 2022 | Publicaciones - CIMO-01 | 0 comments

Minchom, A; Viteri, S; Bazhenova, L; Gadgeel, SM; Ou, SHI; Trigo, J; Bauml, JM; Backenroth, D; Bhattacharya, A; Li, TCY; Mahadevia, P; Girard, N – 2022